AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

04 May 2021 19:53:36 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET

21 Apr 2021 09:18:57 By Nasdaq GlobeNewswire

Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

25 Mar 2021 08:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

09 Mar 2021 17:49:13 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET

05 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback

25 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET

17 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

09 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

28 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update

07 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

04 Jan 2021 07:30:00 By Nasdaq GlobeNewswire